Added to YB: 2026-06-18
Pitch date: 2026-06-16
ENGN [bullish]
enGene Therapeutics Inc.
+6.86%
current return
Author Info
Show me the incentives is a part-time investor focused on pre-deal M&A. Sign up for the newsletter.
Company Info
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Market Cap
$117.2M
Pitch Price
$1.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.83
P/E
-0.83
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
enGene Therapeutics Inc. ($ENGN)
ENGN: Clinical-stage biotech post-80% drop on failed LEGEND bladder cancer trial (13% 12mo cancer-free vs peers). Trades ~56% discount to net cash ($3.39/sh). Activist BML at 9.95% pushing realization. CMO exit, 50% RIF signal wind-down. CEO sold Albireo to Ipsen. Optionality on bladder rinse/BLA H2'26.
Read full article (7 min)